[Anti-tumor immunotherapy based on dendritic cells].
In cancer immunotherapy, the use of dendritic cells (DC) loaded with tumor-associated antigens (TAA) emerged as a promising strategy. We initiated 3 pilot clinical trials with immunological endpoints using TAA loaded autologous DC. These trials showed that this approach was safe and associated with the induction of potent TAA specific IFN-gamma responses, which were transient despite the providing a further help through KLH presentation. Subcutaneous (s.c.) IL-2 administration was associated with long-lasting TAA specific IL-5 production. Clinical responses were observed in about 1/3 of the patients. Further improvements will take advantage of the use of a new type of DC cells (IL-3/IFN-beta DC) and of tumor cell-DC hybrids.
Toungouz
M
M
Unité de thérapie cellulaire et moléculaire, Département d'immunologie-hématologie-transfusion, université libre de Bruxelles (ULB).
Lambermont
M
M
Velu
T
T
Buelens
C
C
Vanderheyde
N
N
Bartholomé
E
E
Willems
F
F
Gangji
D
D
Goldman
M
M
D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000276:immunology*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology / Q000637:transplantation*; D005786:Gene Expression Regulation / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology; D006433:Hemocyanins / Q000276:immunology; D006801:Humans; D006822:Hybrid Cells; D016219:Immunotherapy, Adoptive; D007279:Injections, Subcutaneous; D016899:Interferon-beta / Q000494:pharmacology; D007371:Interferon-gamma / Q000096:biosynthesis; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007377:Interleukin-3 / Q000494:pharmacology; D015847:Interleukin-4 / Q000494:pharmacology; D015848:Interleukin-5 / Q000096:biosynthesis / Q000235:genetics; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010865:Pilot Projects; D016896:Treatment Outcome; D014611:Vaccination
D000951:Antigens, Neoplasm; D007376:Interleukin-2; D007377:Interleukin-3; D015848:Interleukin-5; C072011:MAGEA1 protein, human; C072013:MAGEA3 protein, human; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D015847:Interleukin-4; D016899:Interferon-beta; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin
L'immunothérapie anti-tumorale à base de cellules dendritiques.